Introduction
Materials and methods
Clinical data of the 80 patients with primary FSGS
Variant classification and histological evaluation of glomerular segmental lesions in FSGS
Determination of dominant location and quality of segmental lesions
Grading of other histological lesions
Statistical analysis
Results
Histological variants according to the Columbia classification
Columbia classification (number of cases) | Dominant location/quality factor (number of cases) |
---|---|
COL (13) | TIP-C (2) |
NOS-C (4) | |
NOS-F/C (5) | |
PH-F/C (2) | |
TIP (24) | TIP-C (18) |
TIP-F/C (3) | |
NOS-F/C (1) | |
NOS-F (2) | |
CEL (11) | NOS-C (5) |
NOS-F/C (6) | |
PH (13) | PH-F (13) |
NOS (19) | NOS-F/C (1) |
NOS-F (18) |
Baseline clinical findings and outcomes
Case number | All | COL | TIP | CEL | PH | NOS | ANOVA or Ryan’s test P-value | Multiple comparison (Sheffe) P < 0.05 |
---|---|---|---|---|---|---|---|---|
80 | 13 (16.2%) | 24 (30%) | 11 (13.8%) | 13 (16.2%) | 19 (23.8%) | |||
Age | 39.4 ± 1.7 | 39.9 ± 4.1 | 42.1 ± 3.8 | 44.1 ± 5.3 | 38.1 ± 12.9 | 34.1 ± 2.9 | ns | |
Male/female | 45/35 | 9/4 | 9/15 | 7/4 | 9/4 | 11/8 | ns*1
| |
Interval to Bx (M) | 57.6 ± 8.8 | 41.6 ± 16.2 | 7.8 ± 2.3 | 18.7 ± 5.4 | 136.0 ± 27.7 | 89.0 ± 5.4 | <0.0001 | PH vs. COL, TIP, CEL; NOS vs. TIP, CEL |
sCr (mg/dl) | 1.37 ± 0.11 | 2.04 ± 0.54 | 1.16 ± 0.11 | 1.58 ± 0.18 | 1.08 ± 0.05 | 1.22 ± 0.09 | 0.033 | ns |
sAlb (mg/dl) | 3.34 ± 0.11 | 3.07 ± 0.31 | 2.88 ± 0.20 | 2.84 ± 0.32 | 4.11 ± 0.09 | 3.87 ± 0.10 | <0.0001 | TIP vs. NOS, PH; CEL vs. NOS, PH |
U-p (d/day) | 5.7 ± 0.9 | 7.1 ± 2.6 | 8.8 ± 2.0 | 8.9 ± 2.3 | 2.1 ± 0.5 | 1.7 ± 0.5 | 0.0051 | TIP vs. NOS |
N. synd. | 34/76 (44.7%) | 6/13 (46.2%) | 16/22 (72.7%) | 8/11 (72.7%) | 2/12 (16.7%) | 2/18 (11.1%) | <0.0001*1 (TIP vs. NOS) 0.0012*1 (CEL vs. NOS) |
Case number | All | COL | TIP | CEL | PH | NOS | ANOVA or Ryan’s test P-value |
---|---|---|---|---|---|---|---|
80 | 13 (16.2%) | 24 (30%) | 11 (13.8%) | 13 (16.2%) | 19 (23.8%) | ||
Steroid only | 24/75 (32%) | 3/11 (27.3%) | 14/22 (63.6%) | 4/10 (40%) | 0/13 (0%) | 3/19 (15.8%) | 0.0001*1 (TIP vs. PH) 0.0017*1 (TIP vs. NOS) |
Steroid + IS | 15/75 (20%) | 5/11 (45.5%) | 5/22 (22.7%) | 3/10 (30%) | 0/13 (0%) | 2/19 (10.5%) | ns*1
|
ACEI/ARB only | 24/75 (32%) | 3/11 (27.3%) | 2/22 (9.1%) | 2/10 (20%) | 11/13 (84.6%) | 6/19 (31.6%) | <0.0001*1 (TIP vs. PH) 0.0018*1 (CEL vs. PH) |
0.005*1 (COL vs. PH) 0.0032*1 (NOS vs. PH) | |||||||
LDL apheresis | 7/75 (9.3%) | 1/11 (9.1%) | 2/22 (9.1%) | 4/10 (40%) | 0/13 (0%) | 0/19 (0%) | 0.0011*1 (CEL vs. PH) 0.0012*1 (CEL vs. NOS) |
F/u number of pts | 66 | 10 | 19 | 9 | 10 | 18 | |
F/u duration (m) | 55.9 ± 8.8 | 47.1 ± 12.7 | 79.3 ± 14.0 | 52.6 ± 11.8 | 50.9 ± 13.1 | 38.0 ± 7.8 | ns |
Final U-p (g/day) | 0.97 ± 0.16 | 1.6 ± 0.5 | 0.6 ± 0.3 | 0.9 ± 0.4 | 0.9 ± 0.2 | 1.0 ± 0.3 | ns |
Remission (%) | 37/65 (56.9%) | 4/9 (44.4%) | 16/19 (84.2%) | 6/10 (60%) | 3/10 (30%) | 8/17 (47.1%) | ns*1
|
Final sCr (mg/dl) | 2.83 ± 3.70 | 4.00 ± 1.34 | 1.80 ± 0.61 | 4.84 ± 1.80 | 1.19 ± 0.10 | 2.73 ± 0.70 | ns |
HD (%) | 12/66 (18.2%) | 3/10 (30%) | 2/19 (10.5%) | 3/9 (33.3%) | 0/10 (0%) | 4/18 (22.2%) | ns*1
|
Histological findings
All | COL | TIP | CEL | PH | NOS | ANOVA P value | Multiple comparison (Sheffe) P < 0.05 | |
---|---|---|---|---|---|---|---|---|
% GS | 16.6 ± 1.9 | 21.1 ± 5.9 | 8.0 ± 2.3 | 17.5 ± 4.1 | 16.8 ± 2.9 | 23.6 ± 5.1 | 0.0361 | ns |
% SS | 18.9 ± 1.3 | 20.8 ± 3.7 | 17.1 ± 2.0 | 24.7 ± 5.2 | 16.0 ± 13.0 | 18.6 ± 2.3 | ns | |
% GS + SS | 35.3 ± 2.1 | 41.9 ± 6.1 | 25.1 ± 2.7 | 42.2 ± 5.5 | 32.8 ± 4.0 | 42.2 ± 5.2 | 0.0105 | ns |
IF/TA score (0–3) | 1.53 ± 0.10 | 1.62 ± 0.26 | 1.04 ± 0.16 | 2.10 ± 0.27 | 1.54 ± 0.18 | 1.79 ± 0.18 | 0.0106 | CEL vs. TIP |